Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2022 May 7;29(5):3393-3424.
doi: 10.3390/curroncol29050275.

The Health Economics of Metastatic Hormone-Sensitive and Non-Metastatic Castration-Resistant Prostate Cancer-A Systematic Literature Review with Application to the Canadian Context

Ivan Yanev  1   2 , Jessy Gatete Jr  1   2 , Armen G Aprikian  3 , Jason Robert Guertin  4   5 , Alice Dragomir  1   2   3
Affiliations

The Health Economics of Metastatic Hormone-Sensitive and Non-Metastatic Castration-Resistant Prostate Cancer-A Systematic Literature Review with Application to the Canadian Context

Ivan Yanev et al. Curr Oncol. .

Abstract

Background: Health economic evaluations are needed to assess the impact on the healthcare system of emerging treatment patterns for advanced prostate cancer. The objective of this study is to review the scientific literature identifying cost-effectiveness and cost analyses that are assessing treatments for metastatic hormone-sensitive prostate cancer (mHSPC) and nonmetastatic castration-resistant prostate cancer (nmCRPC). Methods: On 29 June 2021, we searched the scientific (MEDLINE, Embase, and EBSCO) and grey literature for health economic studies targeting mHSPC and nmCRPC. We used the CHEC-extended checklist and the Welte checklist for risk-of-bias assessment and transferability analysis, respectively. Results: We retained 20 cost-effectiveness and 4 cost analyses in the mHSPC setting, and 14 cost-effectiveness and 6 cost analyses in the nmCRPC setting. Docetaxel in combination with androgen deprivation therapy (ADT) was the most cost-effective treatment in the mHSPC setting. Apalutamide, darolutamide, and enzalutamide presented similar results vs. ADT alone and were identified as cost-effective treatments for nmCRPC. An increase in costs as patients transitioned from nmCRPC to mCRPC was noted. Conclusions: We concluded that there is an important unmet need for health economic evaluations in the mHSPC and nmCRPC setting incorporating real-world data to support healthcare decision making.

Keywords: NM-CRPC; clinical trials; cost analysis; cost effectiveness; healthcare-system perspective; mHSPC; prostate cancer; real-world data; review; societal perspective.

PubMed Disclaimer

Conflict of interest statement

The authors declare no conflict of interest.

Figures

Figure 1
Figure 1
PRISMA flow diagram. Abbreviations: CADTH: Canadian Agency for Drugs and Technologies in Health, HTA: health technology assessment, INESSS: Institut national d’excellence en santé et en services sociaux, NICE: National Institute for Health and Care Excellence, mCRPC: metastatic castration-resistant prostate cancer.
See this image and copyright information in PMC

References

    1. Cattrini C., Castro E., Lozano R., Zanardi E., Rubagotti A., Boccardo F., Olmos D. Current Treatment Options for Metastatic Hormone-Sensitive Prostate Cancer. Cancers. 2019;11:1355. doi: 10.3390/cancers11091355. - DOI - PMC - PubMed
    1. Canadian Cancer Statistics Advisory Committee . Canadian Cancer Statistics 2019. Canadian Cancer Society; Toronto, ON, Canada: 2019. [(accessed on 9 March 2022)]. Available online: Cancer.ca/Canadian-Cancer-Statistics-2019-EN.
    1. Saad F., Aprikian A., Finelli A., Fleshner N.E., Gleave M., Kapoor A., Niazi T., North S.A., Pouliot F., Rendon R.A., et al. 2021 Canadian Urological Association (CUA)—Canadian Uro Oncology Group (CUOG) Guideline: Management of Castration-Resistant Prostate Cancer (CRPC) Can. Urol. Assoc. J. 2021;15:E81–E90. doi: 10.5489/cuaj.7074. - DOI - PMC - PubMed
    1. So A.I., Chi K.N., Danielson B., Fleshner N.E., Kapoor A., Niazi T., Pouliot F., Rendon R.A., Shayegan B., Sridhar S., et al. Canadian Urological Association—Canadian Urologic Oncology Group guideline on metastatic castration-naive and castration-sensitive prostate cancer. Can. Urol. Assoc. J. 2019;14:17–23. doi: 10.5489/cuaj.6384. - DOI - PMC - PubMed
    1. Grover S.A. Economics of prostate cancer: A computer model. Can. J. Urol. 1997;4:88–89. - PubMed

Publication types

LinkOut - more resources